Related Experiment Video
Updated: Jun 15, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
[Antiviral effects of entecavir in patients with hepatitis B virus-related cirrhosis]
Yan Xu1, Jiang-bin Wang, Jie Xu
1China-Japan Union Hospital of Jilin University, Changchun 130033, China.
Objective:
To analyze antiviral effects of entecavir in patients with hepatitis B virus-related cirrhosis.
Methods:
104 patients of hepatitis B virus-related cirrhosis with no previous history of antiviral therapy were treated with entecavir 0.5 mg once daily. 37 patients were taken hepatic histologic examination before and after the treatment.
Results:
Mean reductions of serum HBV DNA was 5.1 log10 96 weeks after the treatment, HBV DNA became undetectable in 98.1% patients, and ALT became normal in 80.7% patients; HBeAg seroconversion occurred in 13.9% of the 72 HBeAg positive patients; 61.5% of these patients were infected with genotype C HBV, and 26.9% were infected with genotype B HBV. The genotype of HBV was not associated with the therapeutical effect. Child-pugh score was associated with the progression of the disease: the proportion of patients with disease progression was highest in Child-Pugh C grade patients and lowest in Child-Pugh A grade patients. The level of the HBV DNA load was positively correlated with Knodell HAI score at the baseline and 96 weeks after the treatment.
Conclusion:
Entecavir treatment results in suppression of HBV replication and delayed progression of fibrosis in patients with hepatitis B virus-related cirrhosis.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Antiviral Nucleoside Inhibitors
Inhibitors of Viral Protein Synthesis
Retrovirus Life Cycles
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
